The "black box" warning issued by the FDA in 2007 doesn't seem to be the reason behind the reduced use of erythropoiesis-stimulating agents to treat anemia in dialysis patients, according to a study in the journal BMC Nephrology. Instead, a change in Medicare payments appears to be behind the steady decline.

Related Summaries